Ab&B Bio-Tech Strikes Overseas Vaccine Deal With Walvax Hong Kong; Shares Fall 13%
MT Newswires Live
Mar 16
Ab&B Bio-Tech (HKG:2627) said it has entered into a cooperation agreement with Walvax Hong Kong to expand overseas markets for its subunit influenza vaccine, according to a March 13 Hong Kong bourse filing.
Shares of the biotech firm were down more than 13% in Monday morning trade.
The companies will cooperate on overseas registration, sales, and commercialization of the group's products, with the trivalent subunit influenza vaccine Huierkangxin 3 as the core product for international expansion.
The partnership will leverage Walvax Hong Kong's overseas market resources and distribution networks to accelerate expansion into Southeast Asia, Latin America, the Middle East, and other Southern Hemisphere markets.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.